ArticleOncotarget2017

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.

John E Bisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.